mci 9038 has been researched along with Hemorrhage in 61 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 6 (9.84) | 18.2507 |
2000's | 24 (39.34) | 29.6817 |
2010's | 26 (42.62) | 24.3611 |
2020's | 5 (8.20) | 2.80 |
Authors | Studies |
---|---|
Chen, HS; Cui, Y; Hou, XW; Li, XQ; Tian, XF; Wang, XH; Zhou, ZH | 1 |
Li, X; Li, Y; Sun, B; Tang, X; Tong, Z; Wang, R; Zhang, Z | 1 |
Boyle, G; Buchholz, H; Cantor, RS; Conway, J; Fynn-Thompson, F; Griffiths, E; Hawkins, B; Lorts, A; Lytrivi, ID; Machado, D; May, L; Niebler, RA; Rossano, J; Sutcliffe, DL; VanderPluym, CJ | 1 |
Bergis, B; Chanson, N; Chassin, O; Drouot, S; Gleizes, O; Legris, N; Proulle, V; Ract, C; Walle, EM; Werner, M | 1 |
Lai, CMB; Lee, AYY; Smith, T | 1 |
Banik, N; Beyer-Westendorf, J; Brachmann, J; Dohmen, PM; Eberle, S; Hankowitz, J; Klamroth, R; Kropff, S; Lindhoff-Last, E; Madlener, K; Müller, MM; Pötzsch, B; Schellong, S; Schindewolf, M; Steindl, J | 1 |
Gheysens, O; Goffin, KE; Hoylaerts, MF; Jacquemin, M; Liesenborghs, L; Peerlinck, K; Peetermans, M; Peetermans, WE; Vanassche, T; Verhaegen, J; Verhamme, P; Wijngaerden, EV | 1 |
Pötzsch, B | 1 |
Burger, CF; Schlesinger, JJ | 1 |
Cao, FF; Feng, X; Jiao, RN; Zhang, HT | 1 |
Moffett, BS; Teruya, J | 1 |
Bahlmann, A; Beiderlinden, M; Brezina, T; Geib, J; Golla, E; Greinacher, A; Kienbaum, P; Kindgen-Milles, D; Pannen, B; Schaefer, MS; Treschan, TA; Werner, P | 1 |
Lin, JK; Tong, LM; Vo, QA | 1 |
Baumgarten, G; Boehm, O; Graeff, I; Hoeft, A; Kim, SC; Schewe, JC; Tran, N; Wittmann, M | 1 |
Bain, J; Meyer, A | 1 |
Fushimi, K; Horiguchi, H; Matsubara, T; Nakajima, S; Wada, T; Yahagi, N; Yasunaga, H | 1 |
Baumgarten, G; Kim, S; Koster, A; Riedel, R; Schewe, JC; Schmieder, A | 1 |
Baron, SJ; Cruz-Gonzalez, I; Healy, JL; Jang, IK; Osakabe, M; Sanchez-Ledesma, M; Watanabe, H; Yeh, RW | 1 |
Hursting, MJ; Verme-Gibboney, CN | 1 |
Baron, SJ; Cruz-Gonzalez, I; Healy, JL; Jang, IK; McNulty, IA; Pomerantsev, E; Yeh, RW | 1 |
Dangas, G | 1 |
Jianping, N; Siyuan, D; Yanchao, L; Yixiong, Z | 1 |
Buerke, M; Desaga, M; Genth-Zotz, S; Gulba, DC; Harder, S; Heyndrickx, GR; Rau, M; Rössig, L; Schneider, T; Zeiher, AM | 1 |
Boyle, DA; Choi, YM; Cox, DS; Gobburu, JV; Hossain, M; Madabushi, R; Patel, BR; Young, G | 1 |
Agnihotri, AK; Hoffman, WD; Jang, IK; Nam, KH; Yeh, RW; Yoon, JH | 1 |
Bandyk, DF; Bartholomew, JR; Boyce, SW; Frame, JN; Rice, L | 1 |
Smythe, MA; Warkentin, TE; Woodhouse, AL; Zakalik, D | 1 |
Chen, X; Chen, Y; Ma, Z; Sun, X; Wang, Y; Xiang, J; Xiao, Q; Zhou, J | 1 |
Boshkov, LK; Boyle, DA; Cox, DS; Hursting, MJ; Kallender, H; Raffini, LJ; Soffer, J; Sullivan, JE; Tarka, EA; Young, G | 1 |
Bradley, AM; Branan, T | 1 |
Demma, LJ; Levy, JH; Paciullo, CA | 1 |
Doepker, B; Gerlach, AT; Mount, KL; Murphy, CV; Philips, GS; Ryder, LJ | 1 |
Knovich, MA; Lesser, GJ; Strowd, RE | 1 |
Cooper, T; Kokko, H; Mazur, J; Taber, D; Uber, WE; White, CL | 1 |
Mizuno, Y; Noda, K; Tanaka, R; Urabe, T | 1 |
Buijsman, R; Meuleman, DG; Princen, AW; Smit, MJ; Van Dinther, TG; Vogel, GM | 1 |
Bartholomew, JR; Hursting, MJ | 1 |
McIntosh, BA | 1 |
Koerber, JM; Mattson, JC; Smythe, MA; Stephens, JL | 1 |
Katz, E; Kim, KY; McNulty, I | 1 |
Aghababian, RV; Begelman, SM; Hursting, MJ; McCollum, D | 1 |
Hursting, MJ; Lewis, BE | 1 |
Fischer, KG | 1 |
Beiderlinden, M; Görlinger, K; Peters, J; Treschan, TA | 1 |
Hursting, MJ; Jang, IK | 1 |
Ahmed, I; Majeed, A; Powell, R | 1 |
Lepor, NE | 1 |
Warkentin, TE | 1 |
Verstraete, M | 1 |
Hara, T; Kunitada, S; Morishima, Y; Tanabe, K; Terada, Y | 1 |
Hirayama, F; Kawasaki, T; Koshio, H; Matsumoto, Y; Sato, K; Taniuchi, Y | 1 |
Fukazawa, T; Goto, Y; Hayashi, H; Inoue, Y; Komatsu, Y | 1 |
Jang, IK; Januzzi, JL | 1 |
Ahmad, S; Ahsan, A; Fareed, J; Hoppensteadt, DA; Iqbal, O; Lewis, BE; Walenga, JM | 1 |
Besse, P; Darius, H; Fels, PW; Fitzgerald, D; Garrigou, D; Müller, E; Puel, J; Simoons, ML; Vahanian, A; Van de Werf, F; Vermeer, F | 1 |
Bartholomew, J; Berkowitz, SD; Fareed, J; Hursting, MJ; Jang, IK; Kelton, JG; Lerner, RG; Lewis, BE; Matthai, WH; Moran, J; Rifkin, SD; Rustagi, PK; Sham, R; Walenga, JM; Wallis, DE; Zeigler, ZR | 1 |
Bode, C; Darius, H; Diehm, C; Encke, A; Gulba, DC; Haas, S; Hacke, W; Puhl, W; Quante, M; Riess, H; Scharf, R; Schellong, S; Schrör, T; Schulte, KL; Tebbe, U; Van Aken, H | 1 |
Corno, A; Horisberger, J; Marty, B; Mueller, X; von Segesser, LK | 1 |
Cho, JH; Dan, T; Kim, HY; Koga, T; Koo, BA; Seo, HS; Yun, CH | 1 |
13 review(s) available for mci 9038 and Hemorrhage
Article | Year |
---|---|
Argatroban: for a few selected patients.
Topics: Anticoagulants; Antithrombins; Arginine; Chondroitin Sulfates; Dermatan Sulfate; Drug Interactions; Drug Substitution; Hemorrhage; Heparin; Heparitin Sulfate; Humans; Patient Selection; Pipecolic Acids; Risk Assessment; Risk Factors; Sulfonamides; Thrombocytopenia; Treatment Outcome; Venous Thrombosis | 2013 |
[Anticoagulation].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Arginine; Arrhythmias, Cardiac; Blood Coagulation Tests; Factor Xa Inhibitors; Hemorrhage; Heparin; Heparinoids; Hirudins; Humans; Infusions, Intravenous; Orthopedic Procedures; Peptide Fragments; Pipecolic Acids; Postoperative Complications; Pulmonary Embolism; Recombinant Proteins; Risk Factors; Secondary Prevention; Sulfonamides; Thromboembolism; Treatment Outcome; Venous Thrombosis; Vitamin K | 2013 |
[Meta-analysis of the role of Argatroban in renal replacement therapy].
Topics: Antithrombins; Arginine; Hemorrhage; Humans; Incidence; Pipecolic Acids; Renal Dialysis; Renal Insufficiency; Renal Replacement Therapy; Sulfonamides; Thrombosis | 2013 |
[Heparin-induced thrombocytopenia type II (HIT II) : A medical-economic view].
Topics: Arginine; Chondroitin Sulfates; Costs and Cost Analysis; Dermatan Sulfate; Germany; Hemorrhage; Heparin; Heparitin Sulfate; Hospitalization; Humans; Pipecolic Acids; Risk Factors; Sulfonamides; Thrombocytopenia; Thrombosis; Treatment Outcome | 2017 |
Developing an algorithm for treating heparin-induced thrombocytopenia.
Topics: Algorithms; Anticoagulants; Antigen-Antibody Complex; Arginine; Clinical Trials as Topic; Diagnosis, Differential; Disease Management; Follow-Up Studies; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Hirudins; Humans; Immunoglobulin G; Pipecolic Acids; Platelet Activation; Platelet Count; Platelet Factor 4; Prognosis; Purpura, Thrombocytopenic, Idiopathic; Recombinant Proteins; Sulfonamides; Thrombocytopenia; Thrombophilia; Time Factors | 2004 |
Direct thrombin inhibition during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.
Topics: Angioplasty, Balloon, Coronary; Antithrombins; Arginine; Drug Interactions; Economics, Pharmaceutical; Fibrinolytic Agents; Hemorrhage; Heparin; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Platelet Aggregation Inhibitors; Recombinant Proteins; Sulfonamides; Thrombocytopenia; Thrombosis | 2007 |
Essentials of anticoagulation in hemodialysis.
Topics: Anticoagulants; Arginine; Blood Coagulation; Chondroitin Sulfates; Dermatan Sulfate; Equipment Failure; Hemorrhage; Heparin; Heparitin Sulfate; Hirudins; Humans; Pipecolic Acids; Recombinant Proteins; Renal Dialysis; Renal Insufficiency, Chronic; Sulfonamides | 2007 |
Heparin induced thrombocytopenia: diagnosis and management update.
Topics: Anticoagulants; Arginine; Cardiovascular Surgical Procedures; Chondroitin Sulfates; Dermatan Sulfate; Fibrinolytic Agents; Hemorrhage; Heparin; Heparitin Sulfate; Hirudins; Humans; Pipecolic Acids; Recombinant Proteins; Renal Dialysis; Sulfonamides; Thrombocytopenia; Warfarin | 2007 |
Anticoagulation for acute coronary syndromes: from heparin to direct thrombin inhibitors.
Topics: Acute Disease; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Arginine; Fondaparinux; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Hirudins; Humans; Models, Molecular; Molecular Structure; Myocardial Ischemia; Peptide Fragments; Pipecolic Acids; Platelet Activation; Polysaccharides; Recombinant Proteins; Sulfonamides; Syndrome; Thrombin; Thrombosis | 2007 |
Direct thrombin inhibitors: appraisal of the antithrombotic/hemorrhagic balance.
Topics: Antithrombins; Arginine; Clinical Trials, Phase III as Topic; Fibrinolytic Agents; Hemorrhage; Hirudin Therapy; Hirudins; Humans; Myocardial Infarction; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides | 1997 |
Heparin induced thrombocytopenia: diagnosis and contemporary antithrombin management.
Topics: Ancrod; Arginine; Chondroitin Sulfates; Dermatan Sulfate; Drug Combinations; Fibrinolytic Agents; Forecasting; Gangrene; Hemorrhage; Heparin; Heparitin Sulfate; Hirudin Therapy; Hirudins; Humans; Pipecolic Acids; Platelet Aggregation; Protein C; Recombinant Proteins; Sulfonamides; Thrombin; Thrombocytopenia; Warfarin | 1999 |
Anticoagulation: the present and future.
Topics: Administration, Oral; Amino Acid Chloromethyl Ketones; Anticoagulants; Arginine; Azetidines; Benzylamines; Binding Sites; Biological Availability; Blood Coagulation; Comorbidity; Coumarins; Drug Design; Embolism; Female; Forecasting; Glycine; Guanidines; Heart Diseases; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Hirudin Therapy; Humans; Neoplasms; Pipecolic Acids; Pregnancy; Pregnancy Complications, Hematologic; Prodrugs; Safety; Serine; Stroke; Sulfonamides; Thrombin; Thrombophilia; Thrombosis | 2001 |
Alternatives to unfractionated heparin for anticoagulation in cardiopulmonary bypass.
Topics: Abciximab; Ancrod; Antibodies, Monoclonal; Anticoagulants; Arginine; Cardiopulmonary Bypass; Chondroitin Sulfates; Cross Reactions; Dermatan Sulfate; Drug Combinations; Drug Hypersensitivity; Factor Xa Inhibitors; Hemodilution; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Heparitin Sulfate; Hirudin Therapy; Humans; Immunoglobulin Fab Fragments; Perfusion; Pipecolic Acids; Platelet Aggregation Inhibitors; Protamines; Sulfonamides; Thrombocytopenia; Thrombophilia; Thrombosis; Tirofiban; Tyrosine | 2001 |
14 trial(s) available for mci 9038 and Hemorrhage
Article | Year |
---|---|
Safety and preliminary efficacy of argatroban plus dual antiplatelet therapy for acute mild to moderate ischemic stroke with large artery atherosclerosis.
Topics: Arginine; Arteries; Atherosclerosis; Hemorrhage; Humans; Intracranial Hemorrhages; Ischemic Stroke; Pipecolic Acids; Platelet Aggregation Inhibitors; Prospective Studies; Retrospective Studies; Sulfonamides; Treatment Outcome | 2022 |
Targeting Coagulase Activity in Staphylococcus aureus Bacteraemia: A Randomized Controlled Single-Centre Trial of Staphylothrombin Inhibition.
Topics: Administration, Intravenous; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Arginine; Bacteremia; Belgium; Blood Coagulation; Coagulase; Dabigatran; Enoxaparin; Feasibility Studies; Female; Hemorrhage; Humans; Injections, Subcutaneous; Male; Middle Aged; Partial Thromboplastin Time; Pilot Projects; Pipecolic Acids; Prospective Studies; Staphylococcal Infections; Staphylococcus aureus; Sulfonamides; Thrombin; Thrombosis; Time Factors; Treatment Outcome | 2018 |
Argatroban versus Lepirudin in critically ill patients (ALicia): a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Arginine; Critical Illness; Female; Hemorrhage; Heparin; Hirudins; Humans; Male; Middle Aged; Partial Thromboplastin Time; Pipecolic Acids; Recombinant Proteins; Renal Insufficiency; Renal Replacement Therapy; Sulfonamides; Surgical Procedures, Operative; Thrombocytopenia | 2014 |
Low dose of argatroban saline flushes anticoagulation in hemodialysis patients with high risk of bleeding.
Topics: Anticoagulants; Arginine; Dose-Response Relationship, Drug; Female; Hemorrhage; Humans; Male; Middle Aged; Pipecolic Acids; Renal Dialysis; Sodium Chloride; Sulfonamides | 2010 |
Argatroban for elective percutaneous coronary intervention: the ARG-E04 multi-center study.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Antithrombins; Arginine; Blood Coagulation; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hemorrhage; Heparin; Humans; Male; Middle Aged; Pipecolic Acids; Sulfonamides; Thrombosis | 2011 |
A randomized, open-label pilot study comparing desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis: PREVENT-HIT Study.
Topics: Adolescent; Adult; Aged; Anticoagulants; Arginine; Disease Progression; Female; Hemorrhage; Heparin; Hirudins; Humans; Male; Middle Aged; Pilot Projects; Pipecolic Acids; Platelet Count; Postoperative Complications; Postoperative Period; Recombinant Proteins; Sulfonamides; Thrombin; Thrombocytopenia; Thrombosis; Treatment Outcome; Young Adult | 2011 |
Bleeding risk factors associated with argatroban therapy in the critically ill.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arginine; Bilirubin; Critical Illness; Female; Hemoglobins; Hemorrhage; Humans; Male; Middle Aged; Pipecolic Acids; Platelet Aggregation Inhibitors; Platelet Count; Retrospective Studies; Risk Factors; Sulfonamides | 2012 |
Anticoagulant therapy with a selective thrombin inhibitor for acute cerebral infarction: usefulness of coagulation markers for evaluation of efficacy.
Topics: Acute Disease; Aged; Anticoagulants; Antithrombins; Arginine; Biomarkers; Blood Coagulation; Blood Coagulation Tests; Blood Proteins; Cerebral Infarction; Embolism; Female; Hemorrhage; Humans; Male; Middle Aged; Pipecolic Acids; Stroke; Sulfonamides; Thrombosis; Treatment Outcome | 2002 |
Transitioning from argatroban to warfarin in heparin-induced thrombocytopenia: an analysis of outcomes in patients with elevated international normalized ratio (INR).
Topics: Adult; Aged; Amputation, Surgical; Arginine; Cause of Death; Female; Hemorrhage; Heparin; Humans; Incidence; International Normalized Ratio; Male; Middle Aged; Pipecolic Acids; Retrospective Studies; Risk Assessment; Sulfonamides; Survival Rate; Thrombocytopenia; Thrombosis; Treatment Outcome; Warfarin | 2005 |
Thrombocytopenia following heparin flush.
Topics: Amputation, Surgical; Anticoagulants; Arginine; Catheters, Indwelling; Cause of Death; Diagnosis, Differential; Female; Hemorrhage; Heparin; Humans; Infusions, Intravenous; Male; Middle Aged; Partial Thromboplastin Time; Patient Selection; Pipecolic Acids; Platelet Count; Prospective Studies; Recurrence; Sulfonamides; Therapeutic Irrigation; Thrombocytopenia; Thrombosis; Treatment Outcome | 2005 |
Argatroban anticoagulation in critically ill patients.
Topics: Anticoagulants; Arginine; Critical Illness; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Multiple Organ Failure; Partial Thromboplastin Time; Pipecolic Acids; Sulfonamides; Thrombocytopenia | 2007 |
Clinical laboratory monitoring of a synthetic antithrombin agent, argatroban, using high performance liquid chromatography and functional methods.
Topics: Anticoagulants; Antithrombins; Arginine; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Monitoring; Drug Therapy, Combination; Hemorrhage; Humans; Male; Myocardial Infarction; Pipecolic Acids; Sensitivity and Specificity; Streptokinase; Sulfonamides; Time Factors | 1999 |
Argatroban and alteplase in patients with acute myocardial infarction: the ARGAMI Study.
Topics: Aged; Angiography; Anticoagulants; Arginine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Partial Thromboplastin Time; Pipecolic Acids; Plasminogen Activators; Sulfonamides; Survival Rate; Time Factors; Tissue Plasminogen Activator | 2000 |
Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.
Topics: Aged; Anticoagulants; Arginine; Blood Coagulation; Blood Coagulation Tests; Diarrhea; Exanthema; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Pain; Pipecolic Acids; Purpura; Sulfonamides; Thrombocytopenia; Treatment Outcome | 2001 |
34 other study(ies) available for mci 9038 and Hemorrhage
Article | Year |
---|---|
[Application of argatroban in patients receiving extracorporeal membrane oxygenation support: a case-control study].
Topics: Anticoagulants; Case-Control Studies; Extracorporeal Membrane Oxygenation; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Retrospective Studies; Thrombosis | 2022 |
Utilization and Outcomes of Children Treated with Direct Thrombin Inhibitors on Paracorporeal Ventricular Assist Device Support.
Topics: Adolescent; Antithrombins; Arginine; Child; Child, Preschool; Female; Heart-Assist Devices; Hemorrhage; Hirudins; Humans; Infant; Male; North America; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Retrospective Studies; Stroke; Sulfonamides; Thrombosis; Treatment Outcome | 2020 |
[Complex management of type 2 heparin-induced thrombocytopenia in patients with major bleeding tendency: two case report].
Topics: 4-Hydroxycoumarins; Aged; Anticoagulants; Arginine; Blood Coagulation Disorders; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Hemorrhage; Heparin; Humans; Indenes; Intracranial Thrombosis; Male; Middle Aged; Neurosurgical Procedures; Pipecolic Acids; Sulfonamides; Thrombocytopenia; Vitamin K | 2020 |
Treatment and outcomes of heparin-induced thrombocytopenia (HIT) in patients with neoplasm, a case series.
Topics: Aged; Anticoagulants; Arginine; Canada; Female; Fondaparinux; Gastrointestinal Neoplasms; Hematologic Neoplasms; Hemorrhage; Heparin; Humans; Male; Patient Acuity; Pipecolic Acids; Platelet Count; Retrospective Studies; Risk Adjustment; Sulfonamides; Thrombocytopenia | 2021 |
Use of Fondaparinux Off-Label or Approved Anticoagulants for Management of Heparin-Induced Thrombocytopenia.
Topics: Anticoagulants; Arginine; Chondroitin Sulfates; Dermatan Sulfate; Factor Xa Inhibitors; Female; Fondaparinux; Hemorrhage; Heparin; Heparitin Sulfate; Hirudins; Hospital Mortality; Hospitalization; Humans; Male; Necrosis; Off-Label Use; Partial Thromboplastin Time; Patient Safety; Pipecolic Acids; Polysaccharides; Recombinant Proteins; Registries; Retrospective Studies; Sulfonamides; Thrombocytopenia; Thromboembolism; Treatment Outcome | 2017 |
Intravenous warfarin and heparin-induced thrombocytopenia: making the diagnosis, management, modern monitoring, and multidisciplinary care.
Topics: Aged; Anticoagulants; Antithrombins; Arginine; Cardiac Surgical Procedures; Hemorrhage; Heparin; Humans; Infusions, Intravenous; Male; Pipecolic Acids; Pulmonary Embolism; Sulfonamides; Thrombocytopenia; Thrombosis; Warfarin | 2014 |
Trends in parenteral direct thrombin inhibitor use in pediatric patients: analysis of a large administrative database.
Topics: Adolescent; Age Factors; Antithrombins; Arginine; Child; Child, Preschool; Databases, Factual; Female; Health Information Systems; Hemorrhage; Hirudins; Humans; Incidence; Infant; Infant, Newborn; Infusions, Parenteral; Male; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Retrospective Studies; Sulfonamides; Thrombocytopenia; Young Adult | 2014 |
Efficacy and safety of argatroban and bivalirudine in patients with suspected heparin-induced thrombocytopenia.
Topics: Aged; Anticoagulants; Arginine; Female; Hemorrhage; Heparin; Hirudins; Humans; Male; Middle Aged; Partial Thromboplastin Time; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Retrospective Studies; Sulfonamides; Thrombocytopenia | 2015 |
Safety and economic considerations of argatroban use in critically ill patients: a retrospective analysis.
Topics: Adult; Aged; Anticoagulants; Arginine; Critical Illness; Dose-Response Relationship, Drug; Drug Costs; Female; Germany; Health Care Costs; Hemorrhage; Heparin; Humans; Intensive Care Units; Male; Middle Aged; Pipecolic Acids; Retrospective Studies; Sulfonamides; Thrombocytopenia; Thromboembolism | 2015 |
Comparison of bivalirudin to lepirudin and argatroban in patients with heparin-induced thrombocytopenia.
Topics: Aged; Anticoagulants; Antithrombins; Arginine; Dose-Response Relationship, Drug; Female; Hemorrhage; Heparin; Hirudins; Humans; International Normalized Ratio; Male; Middle Aged; Partial Thromboplastin Time; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Retrospective Studies; Sulfonamides; Thrombocytopenia | 2015 |
Outcomes of Argatroban Treatment in Patients With Atherothrombotic Stroke: Observational Nationwide Study in Japan.
Topics: Adult; Aged; Aged, 80 and over; Antithrombins; Arginine; Case-Control Studies; Cohort Studies; Female; Hemorrhage; Humans; Intracranial Arteriosclerosis; Intracranial Thrombosis; Japan; Male; Middle Aged; Odds Ratio; Pipecolic Acids; Practice Guidelines as Topic; Retrospective Studies; Stroke; Sulfonamides; Treatment Outcome | 2016 |
What is the optimal anticoagulation level with argatroban during percutaneous coronary intervention?
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Arginine; Female; Heart Diseases; Hemorrhage; Heparin; Humans; Male; Middle Aged; Pipecolic Acids; Retrospective Studies; Sulfonamides; Thrombocytopenia; Whole Blood Coagulation Time | 2008 |
Risk factors for major bleeding in patients with heparin-induced thrombocytopenia treated with argatroban: a retrospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arginine; Blood Coagulation; Drug Monitoring; Female; Hemorrhage; Heparin; Humans; Lung Diseases; Male; Middle Aged; Odds Ratio; Partial Thromboplastin Time; Pipecolic Acids; Retrospective Studies; Risk Assessment; Risk Factors; Sulfonamides; Thrombocytopenia; Thrombosis; Young Adult | 2008 |
Anticoagulation with the direct thrombin inhibitor argatroban in patients presenting with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Arginine; Cardiac Catheterization; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Pipecolic Acids; Retrospective Studies; Risk Assessment; Sulfonamides; Thrombin; Treatment Outcome | 2009 |
Clinical investigation in ACS and PCI: shooting in the dark at a moving target.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Arginine; Evidence-Based Medicine; Hemorrhage; Humans; Myocardial Infarction; Myocardial Revascularization; Pipecolic Acids; Research Design; Risk Assessment; Sulfonamides; Thrombin; Treatment Outcome | 2009 |
Pharmacokinetic and pharmacodynamic basis for effective argatroban dosing in pediatrics.
Topics: Adolescent; Arginine; Bilirubin; Body Weight; Child; Child, Preschool; Computer Simulation; Dose-Response Relationship, Drug; Female; Hemorrhage; Humans; Infant; Infant, Newborn; Male; Models, Biological; Partial Thromboplastin Time; Pipecolic Acids; Platelet Aggregation Inhibitors; Sulfonamides | 2011 |
Safety and efficacy of the argatroban therapy during the early post-cardiac surgery period.
Topics: Aged; Aged, 80 and over; Arginine; Cardiac Surgical Procedures; Drug-Related Side Effects and Adverse Reactions; Female; Hemorrhage; Hospital Mortality; Humans; Male; Middle Aged; Pipecolic Acids; Postoperative Care; Postoperative Complications; Retrospective Studies; Sulfonamides; Thrombin; Thrombosis; Treatment Outcome | 2010 |
Venous limb gangrene and fatal hemorrhage: adverse consequences of HIT "overdiagnosis" in a patient with antiphospholipid syndrome.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arginine; Diagnostic Errors; Drug Monitoring; Fatal Outcome; Female; Gangrene; Hemorrhage; Humans; Lung Diseases; Middle Aged; Pipecolic Acids; Sulfonamides; Thrombocytopenia; Upper Extremity; Vascular Diseases; Warfarin | 2011 |
Effects of argatroban as an anticoagulant for intermittent veno-venous hemofiltration (IVVH) in patients at high risk of bleeding.
Topics: Acute Kidney Injury; Anticoagulants; Arginine; Cohort Studies; Female; Follow-Up Studies; Hemofiltration; Hemorrhage; Humans; Male; Middle Aged; Pipecolic Acids; Prognosis; Prospective Studies; Renal Replacement Therapy; Risk Factors; Sulfonamides; Survival Rate | 2011 |
Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: an open-label, safety, efficacy, and pharmacokinetic study.
Topics: Anticoagulants; Arginine; Child; Child, Preschool; Female; Hemorrhage; Heparin; Humans; Infant; Liver Function Tests; Male; Pipecolic Acids; Platelet Aggregation Inhibitors; Prospective Studies; Sulfonamides; Survival Rate; Thrombocytopenia; Thrombosis; Tissue Distribution; Treatment Outcome | 2011 |
Implementation of an individualized argatroban protocol in an academic medical center.
Topics: Academic Medical Centers; Arginine; Clinical Protocols; Hemorrhage; Humans; Pipecolic Acids; Precision Medicine; Prothrombin Time; Retrospective Studies; Sulfonamides | 2011 |
Recognition of heparin-induced thrombocytopenia and initiation of argatroban therapy after cardiothoracic surgery in the intensive care unit.
Topics: Antibodies; Anticoagulants; Arginine; Cardiac Surgical Procedures; Drug Substitution; Georgia; Hemorrhage; Heparin; Humans; Intensive Care Units; Pipecolic Acids; Platelet Factor 4; Predictive Value of Tests; Retrospective Studies; Risk Assessment; Risk Factors; Sulfonamides; Thoracic Surgical Procedures; Thrombocytopenia; Thrombosis; Time Factors; Treatment Outcome | 2012 |
The therapeutic management of bleeding and thrombotic disorders complicating CNS malignancies.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Bevacizumab; Central Nervous System Neoplasms; Fondaparinux; Glioblastoma; Glioma; Hemorrhage; Heparin, Low-Molecular-Weight; Hirudins; Humans; Pipecolic Acids; Polysaccharides; Postoperative Complications; Pulmonary Embolism; Recombinant Proteins; Sulfonamides; Thrombocytopenia; Vena Cava Filters; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2012 |
Safety and effectiveness outcomes of an inpatient collaborative drug therapy management service for direct thrombin inhibitors.
Topics: Adult; Aged; Antithrombins; Arginine; Cohort Studies; Cooperative Behavior; Drug Monitoring; Female; Hemorrhage; Heparin; Hirudins; Humans; Inpatients; Male; Medication Errors; Middle Aged; Outcome Assessment, Health Care; Partial Thromboplastin Time; Peptide Fragments; Pharmacists; Pharmacy Service, Hospital; Pipecolic Acids; Recombinant Proteins; Retrospective Studies; Sulfonamides; Thrombocytopenia; Time Factors | 2012 |
Antithrombotic properties of a direct thrombin inhibitor with a prolonged half-life and AT-mediated factor Xa inhibitory activity.
Topics: Animals; Antithrombin III; Arginine; Blood Coagulation Tests; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Half-Life; Hemorrhage; Heparin; Male; Molecular Structure; Oligosaccharides; Pipecolic Acids; Polysaccharides; Rabbits; Rats; Rats, Wistar; Sulfonamides; Thrombin; Thrombolytic Therapy; Thrombosis | 2003 |
A comparison of lepirudin and argatroban outcomes.
Topics: Aged; Anticoagulants; Arginine; Female; Hemorrhage; Hirudins; Humans; Male; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombin; Treatment Outcome | 2005 |
Heparin-induced thrombocytopenia from venous thromboembolism treatment.
Topics: Amputation, Surgical; Anticoagulants; Arginine; Drug Administration Schedule; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Pipecolic Acids; Platelet Count; Randomized Controlled Trials as Topic; Recurrence; Retrospective Studies; Sulfonamides; Thrombocytopenia; Thromboembolism; Treatment Outcome; Warfarin | 2005 |
Effect of body mass index on Argatroban therapy during percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Arginine; Blood Coagulation; Body Mass Index; Coronary Artery Disease; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Obesity; Pipecolic Acids; Retrospective Studies; Sulfonamides; Thrombocytopenia | 2008 |
Fondaparinux versus direct thrombin inhibitor therapy for the management of heparin-induced thrombocytopenia (HIT)--bridging the River Coumarin.
Topics: Acute Disease; Anticoagulants; Arginine; Blood Coagulation; Factor Xa Inhibitors; Fondaparinux; Hemorrhage; Heparin; Hirudins; Humans; International Normalized Ratio; Pipecolic Acids; Platelet Count; Polysaccharides; Recombinant Proteins; Research Design; Sulfonamides; Thrombin; Thrombocytopenia; Treatment Outcome; Venous Thrombosis; Warfarin | 2008 |
Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants.
Topics: Animals; Anticoagulants; Antithrombin III; Arginine; Bleeding Time; Blood Coagulation; Disease Models, Animal; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecular-Weight; Male; Naphthalenes; Peptide Hydrolases; Pipecolic Acids; Propionates; Rats; Rats, Wistar; Sulfonamides; Thrombin; Thrombosis | 1997 |
Effect of a synthetic factor Xa inhibitor, YM-60828, on blood vessel patency in combination with a thrombolytic agent and on blood loss from the operation site in a rat model of arterial thrombosis.
Topics: Animals; Anticoagulants; Arginine; Blood Loss, Surgical; Carotid Arteries; Carotid Artery Thrombosis; Drug Evaluation, Preclinical; Hemorrhage; Heparin; Male; Naphthalenes; Pipecolic Acids; Piperidines; Rats; Recurrence; Reperfusion; Serine Proteinase Inhibitors; Sulfonamides; Thrombolytic Therapy; Time Factors; Tissue Plasminogen Activator | 1998 |
Pharmacological effects of a novel recombinant hirudin, CX-397, in vivo and in vitro: comparison with recombinant hirudin variant-1, heparin, and argatroban.
Topics: Amino Acid Sequence; Animals; Arginine; Arterial Occlusive Diseases; Arteriovenous Shunt, Surgical; Chlorides; Drug Evaluation, Preclinical; Ferric Compounds; Fibrinolytic Agents; Glass; Hemorrhage; Heparin; Hirudin Therapy; Hirudins; Molecular Sequence Data; Pipecolic Acids; Platelet Aggregation; Platelet Aggregation Inhibitors; Rats; Recombinant Proteins; Sequence Alignment; Sequence Homology, Amino Acid; Serine Proteinase Inhibitors; Sulfonamides; Thrombin; Thrombosis; Vena Cava, Inferior; Venous Thrombosis | 1999 |
Argatroban for treatment of heparin-induced thrombocytopenia.
Topics: Arginine; Health Expenditures; Hemorrhage; Heparin; Humans; Pipecolic Acids; Sulfonamides; Thrombocytopenia; Thrombosis | 2001 |
The antithrombotic efficacy of AT-1459, a novel, direct thrombin inhibitor, in rat models of venous and arterial thrombosis.
Topics: Administration, Oral; Amidines; Animals; Arginine; Azepines; Bleeding Time; Carotid Artery Thrombosis; Dalteparin; Drug Evaluation, Preclinical; Fibrinolytic Agents; Hemorrhage; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Molecular Structure; Pipecolic Acids; Rats; Rats, Sprague-Dawley; Sulfonamides; Thrombin; Vena Cava, Inferior; Venous Thrombosis; Warfarin | 2001 |